Meetings and Courses

Announcements for this section should be submitted in the correct format at least 3 months before the required date of publication. This list is provided as a service to readers; inclusion does not imply endorsement by the HBPD INT.

Section editor

Shui-Ying Lei

Email: hbpdje@gmail.com

June

2014 joint international congress of ILTS, ELITA & LICAGE

June 4-7, 2014; Queen Elizabeth II Conference Center, London, UK

The goal of this congress is to broaden the education of scientists, surgeons, anesthesiologists, physicians, nurses, and organ procurement personnel in the care and treatment of liver transplant patients. The official language of the congress is English. For more information, please visit: http://2014.ilts.org/.

Singapore hepatitis conference (SHC 2014)

June 6-7, 2014; Suntec, Singapore

The Singapore hepatitis conference (SHC 2014) is a historic meeting that will disseminate the latest developments in hepatitis B and C to the region's acclaimed experts. This conference is designed for practicing physicians who manage viral hepatitis and want to hear the latest updates and strategies from the world's leading experts in the field. For further information, please contact: Conference Secretariat for the Singapore hepatitis conference: Tel: 65-6292-4710; Fax: 65-6292-4721; Email: info@shc2014.com. Website: www.shc2014.com.

23rd annual AACR workshop: molecular biology in clinical oncology

July 20-27, 2014; Westin Snowmass, Snowmass Village, Colorado, USA

The goal of this workshop is to provide a substantive overview of the emerging role that molecular biology plays in the clinical world. The organizers are primarily seeking students who are motivated to build a career in translational cancer research, i.e., the exciting research front at the interface between basic research and clinical investigations. Participants will benefit greatly from attending this workshop, because participants will be able to interact closely with experts in the field of molecular biology; discuss relevant literature in molecular biology; better design and implement experiments, especially those incorporating cuttingedge technology; communicate more effectively with their basic science colleagues; and apply the advances of molecular biology to the problems of clinical oncology based on the background and hands-on laboratory training received at this workshop. For more information, please contact Amy Baran, PhD, Program Administrator, at 215-446-7192 or amy.baran@aacr.org.

Emerging trends in antifibrotic drug trials: strategies and endpoints

June 21-22, 2014; Chicago, Illinois, USA

This emerging trends conference will bring together experts from the field with the ultimate goal to generate consensus to facilitate trials of antifibrotics in humans. Goals and learning objectives are to: 1) identify clinical endpoints for antifibrotic treatment; 2) understand the design of clinical trials for antifibrotic treatment; 3) enhance collaborative efforts -- including the FDA and pharmaceutical companies; 4) develop consensus for existing and future trials in fibrosis research. For more information, please visit: http://www.aasld.org/ additionalmeetings/Pages/emergingtrendsantifibrotic. aspx.

August

Integrative molecular epidemiology

August 11-15, 2014; Boston, MA, USA

The integrative molecular epidemiology workshop is a five-day workshop designed to accelerate the training of the next generation of cancer researchers who must be well-skilled in the integration of biology and epidemiology in studies of etiology and outcome. The workshop is primarily targeted toward molecular epidemiologists, but the materials are designed to also be appropriate for geneticists, statisticians, bioinformaticians, molecular biologists, physician scientists, and others who have completed basic course work in epidemiology. The highly qualified faculty assembled to teach this workshop have expertise that spans these disciplines. All lectures and laboratories will be cognizant of issues like feasibility, scalability, quality control, and practical limitations. Formal didactic lectures will take place with extensive time for discussion. "Laboratories" will build upon the information provided in the lectures with problem-solving sessions and "hands-on" applications of statistical and bioinformatic methods. Participants will work collaboratively in small groups throughout the duration of the workshop. For more information, please visit: http://www.aacr.org/home/scientists/meetings--workshops/educational-workshops--special-courses/ integrative-molecular-epidemiology.aspx.

September

8th ILCA annual conference

September 5-7, 2014; Kyoto, Japan

The goals of the International Liver Cancer Association (ILCA) are as follows: 1) is committed to promoting basic, clinical, translational, multi-disciplinary and multi-national liver cancer research, including the development of clinical trials; 2) fosters, encourages and facilitates scientific exchange and dissemination of knowledge; 3) strives to educate physicians, scientists, allied healthcare professionals and the general public at large; 4) will educate international and national health authorities on the diagnosis, prevention and management of liver cancer; 5) values collaboration with other learned societies, governmental organizations, professional associations, groups, institutions and individuals who contribute to progress in the field. For more information, please contact: International Liver Cancer Association (ILCA), Avenue de Tervueren, 300, B-1150 Brussels, Belgium. Tel: 32-0-2-789-2345; Fax: 32-0-2-743-1550; Email: info@ilca-online.org. Website: http://www.ilca2014.-org/.

AASLD/EASL special conference on hepatitis C

September 12-13, 2014; Sheraton New York, New York City, New York, USA

The objectives of this conference are to: 1) evaluate the impact of new strategies for screening of hepatitis C in the United States and abroad; 2) understand the changing global epidemiology of HCV infection; 3) recognize the role and limitations of non-invasive tests for staging hepatic fibrosis; 4) understand the strengths and limitations of recently approved therapeutic regimens compared to first generation triple therapy regimens; 5) understand barriers to care and identify potential solutions to improve global access to new HCV therapies. For more information, please visit: http://www.aasld.org/additionalmeetings/Pages/ hcvspecialconference.aspx.

2nd world congress on controversies in gastroenterology (CIGI)

September 12-14, 2014; Xi'an, China

The 2nd CIGI Congress aims to circulate up-to-date information and provide unique opportunities for world leaders within the field to debate most vital and contentious issues in the field of gastroenterology and endoscopy. This thought-provoking academic dialogue will bring to light the most current clinical and technological questions. The scientific program will include overviews, state of the art lectures and controversial debates. The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment. Through these exciting discussions, key issues will be raised and provide practitioners with tailored recommendations regarding patient care. For more information, please contact: Headquarters & Administration: 53 Rothschild Boulevard, PO Box 68, Tel Aviv, 6100001, Israel. Tel: 972-3-5666166; Fax: 972-3-5666177; Email: Info@comtecmed.com. Comtec China: Suite 405, Universal Center Building, 175 Xiangyang Road South, Shanghai 200031, China. Tel: 86-21-54660460; Fax: 86-21-54660450; Email: china@ comtecmed.com. Website: www.comtecmed.com/CIGI.

November

The Liver Meeting? 2014: postgraduate course--Clinical implications of inflammation and immunity in acute and chronic liver disease and patient care

November 7-8, 2014; Hynes Convention Center, Boston, Massachusetts, USA

Course directors are Gyongyi Szabo, MD, PhD; Kyong-Mi Chang, MD; and Naga Chalasani, MD. This course will provide a comprehensive update on major scientific advancements and state-of-the art medical approaches in hepatology related to the management of patients with liver disease. Information provided at the course will improve care of individual patients and promote liver health. The objectives of this course are to: 1) identify the relevant immune-mediated events contributing to liver pathology and the progression of liver disease; 2) effectively assess needs for early intervention and management in patients with liver diseases with inflammatory components; 3) prevent progression of chronic liver disease by effective use of immunosuppressives, antiviral agents, bile salt therapies. For more information, please visit: http://www.aasld. org/additionalmeetings/Pages/lmpgcourse14.aspx.

10.1016/S1499-3872(14)60036-9)